In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, digs into Suzetrigine—brand name Journavx—the first non-opioid analgesic approved in over two decades. 

You’ll hear how it works, how it compares to hydrocodone/acetaminophen, and why it might be a game-changer for patients at risk of opioid misuse. We’ll also unpack limitations in the clinical trials, cost concerns, dosing nuances, and key drug interactions to watch for. Plus, we’ll share tips for counseling patients and navigating formulary decisions, especially if your site participates in the manufacturer’s pilot program. 

Don’t miss our quick skim graphic and comparison resource to help you make informed decisions.

This is an excerpt from our April 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Article: Explain How Suzetrigine Stacks Up for Acute Pain
• Graphic: New Drug: Suzetrigine (Journavx)
• Resource: Analgesics for Acute Pain in Adults

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools. 

Use code cc1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us Fan Mail

Email us: [email protected]. 

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. 

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.